Targeting RNA polymerase primary σ70 as a therapeutic strategy against methicillin-resistant Staphylococcus aureus by antisense peptide nucleic acid

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Bai, Hui ^a,b,c   Sang, Guojun ^a   You, Yu ^d   Xue, Xiaoyan ^a   Zhou, Ying ^a   Hou, Zheng ^a   Meng, Jingru ^a   Luo, Xiaoxing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b PLA No 451 Hospital   (China)

^c BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^d 309TH HOSPITAL OF PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LYSYLPHENYLALANYLPHENYLALANYLLYSYLPHENYLALANYLPHENYLALANYLLYSYLPHENYLALANYLPHENYLALANYLLYSINE; MESSENGER RNA; PEPTIDE; PEPTIDE NUCLEIC ACID; PPNA2332; RNA POLYMERASE; RNA POLYMERASE PRIMARY SIGMA 70; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; COMPLEMENTARY RNA; DNA DIRECTED RNA POLYMERASE; PROTECTIVE AGENT; RNA POLYMERASE SIGMA 70; SIGMA FACTOR;

ANTIBIOTIC RESISTANCE; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; ENZYME REPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RNA SEQUENCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VANCOMYCIN INTERMEDIATE RESISTANCE STAPHYLOCOCCUS AUREUS; CELL CULTURE; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIAL VIABILITY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MOLECULAR GENETICS; PATHOLOGY; SEQUENCE HOMOLOGY;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PROKARYOTA; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BASE SEQUENCE; CELLS, CULTURED; DNA-DIRECTED RNA POLYMERASES; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; PEPTIDE NUCLEIC ACIDS; PROTECTIVE AGENTS; RNA, ANTISENSE; RNA, MESSENGER; SEQUENCE HOMOLOGY, AMINO ACID; SIGMA FACTOR; STAPHYLOCOCCAL INFECTIONS;

EID: 84855586204     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029886     Document Type: Article

References (42)

1. Ippolito G, Leone S, Lauria FN, Nicastri E, Wenzel RP, (2010) Methicillin-resistant Staphylococcus aureus: the superbug. Int J Infect Dis 14 (Suppl 4): S7-11.
2. Imaz A, Pujol M, Barragan P, Dominguez MA, Tiraboschi JM, et al. (2010) Community associated methicillin-resistant Staphylococcus aureus in HIV-infected patients. AIDS Rev 12: 153-163.
3. Cataldo MA, Taglietti F, Petrosillo N, (2010) Methicillin-resistant Staphylococcus aureus: a community health threat. Postgrad Med 122: 16-23.
4. David MZ, Daum RS, (2010) Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 23: 616-687.
5. Otto M, (2010) Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus. Annu Rev Microbiol 64: 143-162.
6. Tice AD, Rehm SJ, (2010) Meeting the challenges of methicillin-resistant Staphylococcus aureus with outpatient parenteral antimicrobial therapy. Clin Infect Dis 51 (Suppl 2): S171-S175.
7. Rasmussen RV, Fowler VG Jr, Skov R, Bruun NE, (2011) Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA. Future Microbiol 6: 43-56.
8. Welte T, Pletz MW, (2010) Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents 36: 391-400.
9. Forcade NA, Parchman ML, Jorgensen JH, Du LC, Nyren NR, et al. (2011) Prevalence, Severity, and Treatment of Community-Acquired Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Skin and Soft Tissue Infections in 10 Medical Clinics in Texas: A South Texas Ambulatory Research Network (STARNet) Study. J Am Board Fam Med 24: 543-550.
10. Boucher H, Miller LG, Razonable RR, (2010) Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 51 (Suppl 2): S183-S197.
11. Morosini MI, Canton R, (2010) Tolerance and heteroresistance in Gram-positive microorganisms. Med Clin (Barc) 135 (Suppl 3): 16-22.
12. Welsh KJ, Skrobarcek KA, Abbott AN, Lewis CT, Kruzel MC, et al. (2011) Predictors of relapse of methicillin resistant Staphylococcus aureus bacteremia after treatment with vancomycin. J Clin Microbiol 49: 3669-3672.
13. Nannini E, Murray BE, Arias CA, (2010) Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 10: 516-521.
14. Bal AM, Gould IM, (2011) Antibiotic stewardship: overcoming implementation barriers. Curr Opin Infect Dis 24: 357-362.
15. Singh P, Panda D, (2010) FtsZ inhibition: a promising approach for antistaphylococcal therapy. Drug News Perspect 23: 295-304.
16. Wiener-Kronish JP, Pittet JF, (2011) Therapies against virulence products of Staphylococcus aureus and Pseudomonas aeruginosa. Semin Respir Crit Care Med 32: 228-235.
17. Kaslow DC, Shiver JW, (2011) Clostridium difficile and methicillin-resistant Staphylococcus aureus: emerging concepts in vaccine development. Annu Rev Med 62: 201-215.
18. Morell EA, Balkin DM, (2010) Methicillin-resistant Staphylococcus aureus: a pervasive pathogen highlights the need for new antimicrobial development. Yale J Biol Med 83: 223-233.
19. Bennett CF, Swayze EE, (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50: 259-293.
20. Rasmussen LC, Sperling-Petersen HU, Mortensen KK, (2007) Hitting bacteria at the heart of the central dogma: sequence-specific inhibition. Microb Cell Fact 6: 24.
21. Hatamoto M, Ohashi A, Imachi H, (2010) Peptide nucleic acids (PNAs) antisense effect to bacterial growth and their application potentiality in biotechnology. Appl Microbiol Biotechnol 86: 397-402.
22. Geller BL, (2005) Antibacterial antisense. Curr Opin Mol Ther 7: 109-113.
23. Good L, Awasthi SK, Dryselius R, Larsson O, Nielsen PE, (2001) Bactericidal antisense effects of peptide-PNA conjugates. Nat Biotechnol 19: 360-364.
24. Bai H, Xue X, Hou Z, Zhou Y, Meng J, et al. (2010) Antisense antibiotics: a brief review of novel target discovery and delivery. Curr Drug Discov Technol 7: 76-85.
25. Ji Y, Yin D, Fox B, Holmes DJ, Payne D, et al. (2004) Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus. FEMS Microbiol Lett 231: 177-184.
26. Nekhotiaeva N, Awasthi SK, Nielsen PE, Good L, (2004) Inhibition of Staphylococcus aureus gene expression and growth using antisense peptide nucleic acids. Mol Ther 10: 652-659.
27. Meng J, Wang H, Hou Z, Chen T, Fu J, et al. (2009) Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice from lethal sepsis by targeting mecA. Antimicrob Agents Chemother 53: 2871-2878.
28. Oliveira DC, de LH, (2011) Methicillin-Resistance in Staphylococcus aureus Is Not Affected by the Overexpression in Trans of the mecA Gene Repressor: A Surprising Observation. PLoS One 6: e23287.
29. Wright GD, (2009) Making sense of antisense in antibiotic drug discovery. Cell Host Microbe 6: 197-198.
30. Borukhov S, Nudler E, (2008) RNA polymerase: the vehicle of transcription. Trends Microbiol 16: 126-134.
31. Paget MS, Helmann JD, (2003) The sigma70 family of sigma factors. Genome Biol 4: 203.
32. Lane WJ, Darst SA, (2010) Molecular evolution of multisubunit RNA polymerases: sequence analysis. J Mol Biol 395: 671-685.
33. Bai H, Zhou Y, Hou Z, Xue X, Meng J, et al. (2011) Targeting bacterial RNA polymerase: promises for future antisense antibiotics development. Infect Disord Drug Targets 11: 175-187.
34. Eriksson M, Nielsen PE, Good L, (2002) Cell permeabilization and uptake of antisense peptide-peptide nucleic acid (PNA) into Escherichia coli. J Biol Chem 277: 7144-7147.
35. Kern WV, (2010) Management of Staphylococcus aureus bacteremia and endocarditis: progresses and challenges. Curr Opin Infect Dis 23: 346-358.
36. Gould IM, Cauda R, Esposito S, Gudiol F, Mazzei T, et al. (2011) Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? Int J Antimicrob Agents 37: 202-209.
37. Hatamoto M, Ohashi A, Imachi H, (2010) Peptide nucleic acids (PNAs) antisense effect to bacterial growth and their application potentiality in biotechnology. Appl Microbiol Biotechnol 86: 397-402.
38. Williams KJ, Piddock LJ, (1998) Accumulation of rifampicin by Escherichia coli and Staphylococcus aureus. J Antimicrob Chemother 42: 597-603.
39. Deere J, Iversen P, Geller BL, (2005) Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli. Antimicrob Agents Chemother 49: 249-255.
40. Gait MJ, (2003) Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues. Cell Mol Life Sci 60: 844-853.
41. Mellbye BL, Puckett SE, Tilley LD, Iversen PL, Geller BL, (2009) Variations in amino acid composition of antisense peptide-phosphorodiamidate morpholino oligomer affect potency against Escherichia coli in vitro and in vivo. Antimicrob Agents Chemother 53: 525-530.
42. Tilley LD, Hine OS, Kellogg JA, Hassinger JN, Weller DD, et al. (2006) Gene-specific effects of antisense phosphorodiamidate morpholino oligomer-peptide conjugates on Escherichia coli and Salmonella enterica serovar typhimurium in pure culture and in tissue culture. Antimicrob Agents Chemother 50: 2789-2796.